Bleakley Financial Group LLC Decreases Stock Position in Bristol Myers Squibb Company $BMY

Bleakley Financial Group LLC reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 64.1% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 31,582 shares of the biopharmaceutical company’s stock after selling 56,406 shares during the period. Bleakley Financial Group LLC’s holdings in Bristol Myers Squibb were worth $1,462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. OLD Point Trust & Financial Services N A boosted its holdings in shares of Bristol Myers Squibb by 9.7% in the second quarter. OLD Point Trust & Financial Services N A now owns 16,301 shares of the biopharmaceutical company’s stock worth $755,000 after acquiring an additional 1,440 shares during the period. Caliber Wealth Management LLC KS boosted its holdings in shares of Bristol Myers Squibb by 95.7% in the second quarter. Caliber Wealth Management LLC KS now owns 7,257 shares of the biopharmaceutical company’s stock worth $336,000 after acquiring an additional 3,549 shares during the period. Rehmann Capital Advisory Group boosted its holdings in shares of Bristol Myers Squibb by 6.9% in the second quarter. Rehmann Capital Advisory Group now owns 36,700 shares of the biopharmaceutical company’s stock worth $1,699,000 after acquiring an additional 2,372 shares during the period. Parcion Private Wealth LLC boosted its holdings in shares of Bristol Myers Squibb by 5.8% in the second quarter. Parcion Private Wealth LLC now owns 6,303 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 345 shares during the period. Finally, Steel Grove Capital Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 12.0% in the second quarter. Steel Grove Capital Advisors LLC now owns 38,298 shares of the biopharmaceutical company’s stock worth $1,773,000 after acquiring an additional 4,108 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $43.84 on Friday. The firm has a market capitalization of $89.24 billion, a price-to-earnings ratio of 17.68, a P/E/G ratio of 2.29 and a beta of 0.33. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33. The stock has a fifty day moving average of $45.75 and a 200 day moving average of $47.14. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same quarter in the previous year, the company posted $2.07 earnings per share. The company’s revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.7%. Bristol Myers Squibb’s payout ratio is 100.00%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.09% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BMY shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Finally, Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $57.23.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.